Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Angebot

COVID-19: A Greek university with ultra rapid and sensitive test kit for the mass detection of SARS-CoV-2 virus seeks clinical research or manufacturing partners

Country of Origin: Greece
Reference Number: TOGR20200604001
Publication Date: 5 June 2020

Summary

A Greek university has developed a novel device for detecting COVID-19 in 1-3 minutes, costing € 2-3 per sample, with a capacity of 100 per hour, as well as catching infections early on. The Greek university is interested in finding partners for conducting clinical research under technical cooperation agreements and manufacturers for massive production and commercial exploitation.

Description

A Greek university has developed a novel device for detecting COVID-19 rapidly (1-3 minutes) and with low cost (2-3 euros per sample). The solution has capacity to test up to 100 samples per hour and it is very sensitive as it can detect suspected cases 1 to 3 days after the infection. The solution is suitable for mass population screening in critical areas of interest such as airports whereas it can be easily managed through a tablet or a mobile phone alongside with a commercially available biosensor, which is currently offered by a collaborating company. The technology is characterized by high level of maturity and it is very close to the market (TRL 8). 
The tests developed are based on a methodology measuring the changes in the electrical properties of the antibodies produced after the infection from SARS-CoV-2 and they have several advantages comparing to other alternative solutions already available on the market that have been proven to have certain limitations. The main type of tests currently used for the detection of COVID-19 are based on the real-time reverse transcriptase PCR (called in short RT-PCR) methodology. Despite of the fact that they are characterized by high sensitivity they lack of the adequate throughput capacity required for mass screening considering that that they can only be implemented by certified laboratories and that at least 2 hours are required for their completion putting aside the time needed for the sample collection, the shipping and the processing. Alternatively the other major type of antibody tests (called in short Cas) are economic and fast, nevertheless they are still not fully reliable as in the optimal case they are only able to detect COVID-19, 4 days after the infection. Finally the Cas based tests which have been recently reported in the literature appear to be profoundly time consuming considering that they also require RNA extraction.
The Greek university is interested in finding partners for conducting clinical trials or manufacturers interested for massively producing and distributing the tests.
Image

Advantages and Innovations

Comparing to other tests available in the market the offered tests have the following advantages:

• They may extract results in a fast and reliable manner without having to transfer samples to laboratories
• They have low price
• They are suitable for mass testing

Stage Of Development

Available for demonstration

Requested partner

The Greek university is interested in finding partners for conducting clinical trials or manufacturers massively producing and distributing the tests. The university is interested to bring the solution to the market. For this task, a pharmaceutical company would be the ideal partner for coordinating the clinical trials, the manufacture of the test in large numbers and the commercial exploitation.

Cooperation offer ist closed for requests